Polymer Biomaterial Market Report 2025

This Polymer Biomaterial market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The polymer biomaterial market size has grown exponentially in recent years. It will grow from $79.06 billion in 2024 to $94.98 billion in 2025 at a compound annual growth rate (CAGR) of 20.1%. The growth in the historic period can be attributed to increasing demand for medical devices, growing awareness of the benefits of polymer biomaterials, rising prevalence of chronic diseases, growing demand for polymer biomaterials in ophthalmology.

The polymer biomaterial market size is expected to see rapid growth in the next few years. It will grow to $169.88 billion in 2029 at a compound annual growth rate (CAGR) of 15.6%. The growth in the forecast period can be attributed to customized and personalized medicine, regenerative medicine, 3d printing and biofabrication, aging population. Major trends in the forecast period include advanced drug delivery, bioresorbable polymers, nanotechnology integration, combination therapies, sustainability and biodegradability, smart and responsive materials, biocompatibility advancements.

The global polymer biomaterials market is experiencing significant growth due to the expanding applications of polymeric biomaterials in tissue engineering. Polymers play a vital role in regenerative medicine and tissue engineering, offering flexibility and versatile properties that allow tailoring damaged tissue's physical, chemical, and mechanical properties. Their modifiability during synthesis, adapting to tissue regeneration capabilities, makes them valuable in various tissue engineering applications. Biodegradability, along with diverse geometry and structures, further enhances their suitability for specific tissue engineering needs. This expanding role of polymer biomaterials in tissue engineering is forecasted to drive market growth in the coming years.

The rising prevalence of chronic diseases is anticipated to drive the expansion of the polymer biomaterial market. Chronic diseases, also known as non-communicable diseases (NCDs), are long-lasting medical conditions that persist and often progress gradually over time. Polymer biomaterials are used in the development of implantable devices like drug pumps and electrodes for neuromodulation, which help manage symptoms and enhance patients' quality of life. For example, in June 2024, the UK's National Health Service reported that 3,615,330 people were registered with a GP as having non-diabetic hyperglycemia (pre-diabetes) in 2023, up from 3,065,825 in 2022 - an increase of nearly 18%. Consequently, the growing incidence of chronic diseases is fueling the growth of the polymer biomaterial market.

Leading companies in the polymer biomaterials market are concentrating on innovative solutions, such as osteoconductive biomaterials, to improve tissue integration, support bone regeneration, and enhance patient outcomes across orthopedic and medical applications. Osteoconductive biomaterials encourage bone growth along their surfaces or within their porous structures, providing a scaffold that supports new bone formation and promotes integration with surrounding tissues. For example, in March 2022, Evonik, a chemical company based in Germany, introduced VESTAKEEP Fusion PEEK filament for 3D-printed implants. This advanced osteoconductive biomaterial is designed to improve bone integration through enhanced osteointegration. Incorporating biphasic calcium phosphate additives, the filament facilitates rapid bone cell adhesion and accelerates healing. Additionally, its compatibility with extrusion-based 3D printing technologies enables the production of customized implant designs, catering to individual patient needs while ensuring biocompatibility and long-term stability.

Leading players in the polymer biomaterial market are pioneering new technologies such as Enzymatic Biomaterials (DEB) to bolster their market profitability. Enzymatic Biomaterials (DEB) technology, a novel platform designed for producing high-performing polysaccharides, offers an entirely new approach. For instance, in June 2023, International Flavors & Fragrances Inc. introduced Enzymatic Biomaterials (DEB) technology, a sustainable biopolymer platform enabling the creation of biopolymers with superior performance akin to petroleum-based polymers. This innovative platform facilitates customization and fine-tuning of biopolymer characteristics by directly transferring functionalities from petroleum-based polymer materials, signaling a significant leap in sustainable biopolymer production.

In July 2023, Biocoat, a U.S.-based company specializing in biocompatible coatings for medical devices, acquired Chempilots for an undisclosed sum. This acquisition was part of Biocoat's strategy to strengthen its expertise in polymer development and broaden its product offerings in the biomedical sector. Chempilots, a Denmark-based company, is known for its advanced polymer solutions that contribute to the development of cutting-edge medical technologies.

Polymer biomaterials, composed of pharmacologically inert substances sourced from natural or synthetic origins, serve to augment the functionality of damaged tissues and organs in various therapeutic treatments.

Key types of polymer biomaterials encompass silicone rubber, polyester, polymethyl methacrylate (PMMA), polyethylene (PE), polyvinyl chloride, among others. Silicone rubber within polymer biomaterials denotes a lightly cross-linked rubber matrix integrated with a polyacrylamide hydrogel, utilized for medical and biological applications. These biomaterials vary in nature, spanning both natural and synthetic compositions. Their applications span a wide array of medical fields including cardiovascular treatment, ophthalmology, dental procedures, plastic surgery, wound healing, tissue engineering, orthopedics, neurological disorders impacting the central nervous system, and more.

The polymer biomaterial market research report is one of a series of new reports that provides polymer biomaterial market statistics, including polymer biomaterial industry global market size, regional shares, competitors with a polymer biomaterial market share, detailed polymer biomaterial market segments, market trends and opportunities, and any further data you may need to thrive in the polymer biomaterial industry. This polymer biomaterial market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Major companies operating in the polymer biomaterial market include BASF SE, Corbion N.V., Zimmer Biomet Holdings Inc., Royal DSM N.V., Covestro AG, Evonik Industries AG, Starch Medical Inc., Victrex plc, W. L. Gore and Associates Inc., Bayer AG, DSM Biomedical B.V., Purac Biomaterials, Ticona LLC, Invibo LLC, Covalon Technologies Ltd., Osteotech Inc., Medtronic plc, Stryker Corporation, Synthes Inc., Mitsui & Co. Ltd., Polyfibre Industries Pte Ltd., Toray Industries Inc., Stein Fibers Ltd., Diyou Fiber Corporation, Bezwada Biomedical LLC, Collagen Solutions plc, Cam Bioceramics B.V., CeramTec GmbH, Gelita AG, AorTech Biomaterials Pty Ltd., Berkeley Advanced Biomaterials Inc., Biocomposites Ltd., BioHorizons IPH Inc., Biomerics LLC, Bioteque Corporation, Carpenter Technology Corporation, CollPlant Holdings Ltd., CoorsTek Inc., EndoShape Inc., Heraeus Medical Components LLC, Kyocera Corporation, PolyNovo Biomaterials Pty Ltd., Secant Group LLC.

North America was the largest region in the polymer biomaterials market in 2024. Western Europe was the second-largest region in the global polymer biomaterials market report. The regions covered in the polymer biomaterial market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the polymer biomaterial market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The polymer biomaterials market consists of sales of PCL, PVDF, PLGA, PVP, and nylon. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.